These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 17094780

  • 1. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y.
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW.
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 4. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivistö KT.
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [Abstract] [Full Text] [Related]

  • 5. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J, Faülhaber HD.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
    Germino FW, Lin Y, Pejović V, Bowen L.
    Ther Adv Cardiovasc Dis; 2012 Oct 27; 6(5):185-99. PubMed ID: 23008339
    [Abstract] [Full Text] [Related]

  • 7. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ, Agrawal R, Lichtenthal A, Mäkel W, Fici F.
    Am J Ther; 2006 Oct 27; 13(3):192-7. PubMed ID: 16772759
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ, Saunders E, Greathouse M.
    Clin Ther; 2011 Sep 27; 33(9):1150-61. PubMed ID: 21864908
    [Abstract] [Full Text] [Related]

  • 9. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 27; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 10. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
    Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM.
    J Cardiovasc Pharmacol; 1993 Jun 27; 21(6):856-62. PubMed ID: 7687708
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V.
    Am J Cardiol; 2009 Jan 15; 103(2):273-8. PubMed ID: 19121451
    [Abstract] [Full Text] [Related]

  • 12. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
    Georgescu A, Popov D, Dragan E, Dragomir E, Badila E.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):149-58. PubMed ID: 17612521
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
    Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G.
    Blood Press Suppl; 2003 Dec 10; 2():35-40. PubMed ID: 14761075
    [Abstract] [Full Text] [Related]

  • 14. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
    Lindamood C, Ortiz S, Shaw A, Rackley R, Gorski JC.
    J Clin Pharmacol; 2011 Apr 10; 51(4):575-85. PubMed ID: 20489028
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
    Heitmann J, Greulich T, Reinke C, Koehler U, Vogelmeier C, Becker HF, Schmidt AC, Canisius S.
    Curr Med Res Opin; 2010 Aug 10; 26(8):1925-32. PubMed ID: 20560730
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial.
    Punzi H, Lewin A, Lukić T, Goodin T, Wei Chen.
    Ther Adv Cardiovasc Dis; 2010 Dec 10; 4(6):349-57. PubMed ID: 21088095
    [Abstract] [Full Text] [Related]

  • 17. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
    Zateyshchikov DA, Minushkina LO, Brovkin AN, Savel'eva EG, Zateyshchikova AA, Manchaeva BB, Nikitin AG, Sidorenko BA, Nosikov VV.
    Fundam Clin Pharmacol; 2007 Aug 10; 21(4):437-43. PubMed ID: 17635183
    [Abstract] [Full Text] [Related]

  • 18. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov 10; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 19. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
    Pesant Y, Marc-Aurèle J, Bielmann P, Alaupovic P, Cartier P, Bichet D, Thibault G, Lupien PJ.
    Am J Ther; 1999 May 10; 6(3):137-47. PubMed ID: 10423656
    [Abstract] [Full Text] [Related]

  • 20. Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients.
    Malacco E.
    Eur Rev Med Pharmacol Sci; 2010 May 10; 14(5):427-34. PubMed ID: 20556921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.